Biocon Biologics, a subsidiary of India-based Biocon Ltd, said on Thursday that U.S. FDA has approved Jobevne, a biosimilar ...

Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar ...

Biocon Biologics, a subsidiary of Biocon Ltd, announced on Thursday that it has received approval from the United States Food ...

The US sales of bevacizumab were around $2 billion in 2023. Amgen, Amneal, Celltrion and Pfizer are its competitors in the US ...

Shares of Biocon will be in focus in Friday after the pharma major said its subsidiary Biocon Biologics said the U.S. Food ...

Biocon Biologics, the biosimilar arm of Biocon has expanded its oncology portfolio with the USFDA approval of Jobevne, a ...

BRIDGEWATER, N.J. and BENGALURU, India, April 10, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the ...

Biocon Biologics (BBL), a subsidiary of Biocon, today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous ...

FDA approves Biocon Biologics' Jobevne, a biosimilar Bevacizumab for cancer treatment, expanding access to affordable ...

Biocon Biologics, a subsidiary of Biocon, has scored a major win with the U.S. FDA approving JOBEVNE (bevacizumab-nwgd), a biosimilar to Roche's blockbuster cancer drug Avastin.

Biocon Biologics on Thursday said it has received an approval from the US health regulator to market a cancer treatment ...

Biocon Biologics receives USFDA approval for Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for treating various ...